Man­aT Bio, a KRAS biotech from Bert Vo­gel­stein and Catalio, tar­gets $153M with Third Rock part­ner as CEO

A new im­munother­a­py biotech from famed Johns Hop­kins on­col­o­gy re­searchers Bert Vo­gel­stein and Drew Par­doll is in the works, with a siz­able $153 mil­lion fi­nanc­ing round un­der­way.

Vo­gel­stein, who has found­ed can­cer de­tec­tion com­pa­nies like Thrive and Haystack On­col­o­gy, has been work­ing on a “mul­ti-year col­lab­o­ra­tion” with Par­doll to find mu­ta­tion-as­so­ci­at­ed neoanti­gens (hence MAN­As) that show up on the cell sur­face, ac­cord­ing to the com­pa­ny’s in­cu­ba­tor, Catalio Cap­i­tal Man­age­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER